Case Comment - DMRC LTD. V. DELHI AIRPORT METRO EXPRESS (P) LTD
By Pragya Thakur
In this case, the Supreme Court allowed the curative petitions and set aside its own earlier judgment restoring an arbitral award, holding that the award was vitiated by patent illegality and that its restoration had caused a grave miscarriage of justice
JUDGES
Dr D.Y. Chandrachud, C.J. (author)
B.R. Gavai, J.
Surya Kant, J.
PARTIES
Appellant: Delhi Metro Rail Corporation Limited (DMRC)
Respondent: Delhi Airport Metro Express (Private) Limited (DAMEPL)
CASE DETAILS
Case Number: Curative Petitions (C) Nos. 108-109 of 2022 in Review Petitions (C) Nos. 1158-59 of 2021 in Civil Appeals Nos. 5627-28 of 2021
Decided: April 10, 2024
Reported: (2024) 6 SCC 357
Tags: Arbitration and Conciliation Act 1996, Section 34, Section 37, Patent Illegality, Curative Jurisdiction, Article 137, Article 142, Public-Private Partnership, Concession Agreement, DMRC, Metro Railways Act 2002.
KEY ISSUES
1. Whether the curative petition was maintainable, given the limited scope of curative jurisdiction under Article 142?
2. Whether the Supreme Court, in the earlier appellate round, was justified in restoring the arbitral award which had been set aside by the Division Bench of the Delhi High Court on the ground of patent illegality?
CASE DESCRIPTION
The petitioner, Delhi Metro Rail Corporation (“DMRC”), is a State-owned company, and the respondent, Delhi Airport Metro Express (P) Ltd. (“DAMEPL”), is a special-purpose vehicle organisation formed by a consortium comprising Reliance Infrastructure and a Spanish construction company. The consortium bagged the contract for the construction, operation, and maintenance of Delhi Airport Metro Express Ltd. (“AMEL”) in 2008, a public-private partnership connecting New Delhi Railway Station to the Indira Gandhi International Airport.
In 2012, DAMEPL halted operations alleging that the line was structurally unsafe, and issued a notice listing defects. DMRC was therefore requested to cure the defects within 90 days, failing which it stated that it would be considered a ‘material breach’ and that a “DMRC event of default” had been occasioned, entitling DAMEPL to terminate the 2008 agreement.
On 8-10-2012, DAMPEL issued a notice terminating the 2008 agreement. It stated that as 90 days had elapsed since the notice, the defects had not been cured.
DMRC initiated conciliation, and since the conciliation could not succeed, DMRC initiated arbitral proceedings. In 2017, a three-member tribunal passed a unanimous award in favour of DAMEPL and awarded over Rs 2,782 crores plus interest, along with other sums.
DMRC challeng to the award under Section 34 of the Arbitration Act, 1996 failed before a Single Judge, but a Division Bench partly allowed the appeal, setting aside the award as perverse and patently illegal because the tribunal had disregarded the significance of a safety certificate issued by the Commissioner of Metro Railway Safety (CMRS) and had blurred the distinction between "curing" a defect and taking "effective steps" to cure it. DAMEPL then obtained a reversal from a two-Judge Bench of the Supreme Court under Article 136, restoring the award; DMRC's review petition against that reversal was dismissed, leading DMRC to file the present curative petitions.
A three-Judge Bench allowed the curative petitions, holding that the Court's earlier interference exceeded the narrow scope of Article 136/137 review over a Section 37 decision, and that restoring an award suffering from patent illegality had caused a grave miscarriage of justice warranting the rare exercise of curative jurisdiction under Article 142.
JUDGEMENT AND REASONING OF THE COURT
Delivering the opinion for a unanimous three-Judge Bench, Dr D.Y. Chandrachud, C.J. first addressed the maintainability of the curative petitions. Reaffirming Rupa Ashok Hurra v. Ashok Hurra, the Court held that curative jurisdiction, though exceptional, is not confined to breach of natural justice or bias, and extends to cases causing a "grave miscarriage of justice." On this basis, the petitions were held maintainable.
On the scope of review, the Court reiterated that under Section 34(2-A), an award is patently illegal if the arbitrator's view is such that no reasonable person could take, or if it ignores vital evidence .
On merits, the Court held that Clause 29.5.1(i) contained two distinct standards—curing a defect, or taking effective steps toward cure. The Tribunal wrongly conflated these, treating incomplete cure as proof that no effective steps existed, an interpretation "not even a possible view," rendering the phrase "effective steps" otiose.
Concluding that the arbitral process had been perverted to confer an undue windfall on DAMEPL at DMRC's expense, the Court held that the 2021 judgment's interference caused a grave miscarriage of justice. The curative petitions were allowed, the Division Bench's judgment restored, and the parties directed to be placed in their pre-2021 position, with execution proceedings and payments accordingly undone.
ANALYSIS
The true significance of DMRC v. DAMEPL lies not in its outcome but in the precedent it sets for the relationship between finality and correctness in Indian arbitration. For over two decades, Indian courts have laboured to narrow judicial interference with arbitral awards from Saw Pipes' expansive reading of "public policy" to the corrective course charted in Associate Builders and reinforced in Ssangyong and Dyna Technologies, all converging on the principle that an arbitrator, not a court, is the final judge of evidence and contractual construction.
By using curative jurisdiction conceived in Rupa Hurra as a remedy for breaches of natural justice or bias to revisit the Tribunal's evidentiary findings on the CMRS certificate and the meaning of "effective steps," the Court effectively converted a safety-valve remedy into a substantive fourth or fifth round of merits review.
The Tribunal's interpretation of Clause 29.5.1(i)—collapsing "curing" a defect and "taking effective steps" into a single standard—produced a genuinely awkward result, rendering part of the contractual text redundant. Courts are rightly reluctant to let arbitral awards stand when they ignore a document as consequential as a statutory safety certification, particularly where a public utility bears the resulting liability. Yet this reasoning, however sound in isolation, sits at odds with the composition and purpose of the arbitral tribunal in question. Infrastructure disputes of this technical character are deliberately entrusted to engineer-arbitrators precisely because courts are not well positioned to second-guess judgments on structural safety and repair adequacy.
The greater difficulty, however, lies in the vehicle chosen to deliver this correction. Curative jurisdiction under Article 142 was conceived in Rupa Hurra as an extraordinary safety valve for breaches of natural justice or bias, not as a mechanism for revisiting substantive findings on patent illegality after both appeal and review have been exhausted. By invoking "grave miscarriage of justice" to reopen a judgment that had already survived two rounds of scrutiny, the Court risks normalising curative relief as a de facto fourth appellate tier, notwithstanding its own express caution against precisely this outcome. This tension between the correctness of the substantive reasoning and the exceptional nature of the remedy invoked is likely to generate continuing debate: does the judgment vindicate the sanctity of specialised arbitral fact-finding against erroneous appellate substitution, or does it quietly erode the finality that arbitration and the curative jurisdiction itself were designed to protect?
CONCLUSION
DMRC v. DAMEPL reaffirms that patent illegality remains a vital safeguard against perverse arbitral awards, even at the curative stage. Yet by stretching Rupa Hurra's narrow threshold, the judgment risks diluting finality, arbitration's core promise, raising enduring questions about the appropriate limits of curative intervention in commercial disputes.